Fi­bro­Gen CEO: Roxa path blocked as As­traZeneca re­mains un­de­cid­ed on just what it plans to do in the wake of a CRL

Fi­bro­Gen CEO En­rique Con­ter­no hasn’t giv­en up on the US mar­ket when it comes to their ane­mia drug rox­adu­s­tat. But with As­traZeneca ex­ecs re­fus­ing to budge, so far, on fund­ing a new study to sat­is­fy the FDA, that drug re­mains in lim­bo when it comes to their biggest mar­ket op­por­tu­ni­ty.

Talk­ing to an­a­lysts Mon­day evening, Con­ter­no made it clear that he’s been seek­ing some kind of arrange­ment to push ahead, but so far the phar­ma gi­ant re­mains stuck be­tween green and red lights. And that has some an­a­lysts look­ing for some oth­er way for­ward — with­out As­traZeneca call­ing the shots.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER